Chemomab Therapeutics (CMMB) Cash & Current Investments (2017 - 2025)

Chemomab Therapeutics has reported Cash & Current Investments for 9 years, with the latest figure at $10.4 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Current Investments rose 68.64% year-over-year to $10.4 million; the trailing twelve-month figure through Dec 2025 stood at $10.4 million (up 68.64% YoY), and the FY2025 full-year result was $10.4 million, up 68.64% from the prior year.
• Cash & Current Investments for Q4 2025 stood at $10.4 million, up from $10.1 million in the prior quarter.
• The five-year high for Cash & Current Investments was $66.9 million in Q2 2021, with the low at $6.1 million in Q4 2024.
• Historically, Cash & Current Investments has averaged $27.9 million across 5 years, with a median of $17.6 million in 2024.
• Annual changes were most pronounced in 2021 — Cash & Current Investments surged 849.59% — and 2023, when it sank 54.01%.
• Chemomab Therapeutics' Cash & Current Investments stood at $15.2 million in 2021, then decreased by 10.47% to $13.6 million in 2022, then slumped by 31.1% to $9.4 million in 2023, then sank by 34.38% to $6.1 million in 2024, then jumped by 68.64% to $10.4 million in 2025.
• The last three Cash & Current Investments figures came in at $10.4 million (Q4 2025), $10.1 million (Q3 2025), and $9.4 million (Q2 2025), per Business Quant data.